Home > Publications Database > Neuroinflammation in Alzheimer's disease. > print

001     137851
005     20240618103011.0
024 7 _ |a 10.1016/S1474-4422(15)70016-5
|2 doi
024 7 _ |a pmid:25792098
|2 pmid
024 7 _ |a pmc:PMC5909703
|2 pmc
024 7 _ |a 1474-4422
|2 ISSN
024 7 _ |a 1474-4465
|2 ISSN
024 7 _ |a altmetric:3808150
|2 altmetric
037 _ _ |a DZNE-2020-04173
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Heneka, Michael
|0 P:(DE-2719)2000008
|b 0
|e First author
245 _ _ |a Neuroinflammation in Alzheimer's disease.
260 _ _ |a London
|c 2015
|b Lancet Publ. Group
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2015-04-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1718699372_13420
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterised by release of inflammatory mediators, which contribute to disease progression and severity. Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction. External factors, including systemic inflammation and obesity, are likely to interfere with immunological processes of the brain and further promote disease progression. Modulation of risk factors and targeting of these immune mechanisms could lead to future therapeutic or preventive strategies for Alzheimer's disease.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 1
542 _ _ |i 2015-04-01
|2 Crossref
|u https://www.elsevier.com/tdm/userlicense/1.0/
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Anti-Inflammatory Agents, Non-Steroidal
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Inflammation Mediators
|2 NLM Chemicals
650 _ 7 |a Nootropic Agents
|2 NLM Chemicals
650 _ 2 |a Alzheimer Disease: genetics
|2 MeSH
650 _ 2 |a Alzheimer Disease: immunology
|2 MeSH
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a Alzheimer Disease: prevention & control
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Anti-Inflammatory Agents, Non-Steroidal: therapeutic use
|2 MeSH
650 _ 2 |a Astrocytes: immunology
|2 MeSH
650 _ 2 |a Astrocytes: pathology
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Brain Injuries: complications
|2 MeSH
650 _ 2 |a Brain Injuries: metabolism
|2 MeSH
650 _ 2 |a Clinical Trials as Topic
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Immunity, Innate
|2 MeSH
650 _ 2 |a Immunization
|2 MeSH
650 _ 2 |a Inflammation: diagnosis
|2 MeSH
650 _ 2 |a Inflammation: immunology
|2 MeSH
650 _ 2 |a Inflammation: metabolism
|2 MeSH
650 _ 2 |a Inflammation Mediators: immunology
|2 MeSH
650 _ 2 |a Inflammation Mediators: metabolism
|2 MeSH
650 _ 2 |a Locus Coeruleus: pathology
|2 MeSH
650 _ 2 |a Microglia: immunology
|2 MeSH
650 _ 2 |a Microglia: pathology
|2 MeSH
650 _ 2 |a Nootropic Agents: administration & dosage
|2 MeSH
650 _ 2 |a Obesity: complications
|2 MeSH
650 _ 2 |a Obesity: metabolism
|2 MeSH
650 _ 2 |a Phagocytosis
|2 MeSH
650 _ 2 |a Protein Folding
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
650 _ 2 |a Severity of Illness Index
|2 MeSH
700 1 _ |a Carson, Monica J
|b 1
700 1 _ |a El Khoury, Joseph
|b 2
700 1 _ |a Landreth, Gary E
|b 3
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 4
700 1 _ |a Feinstein, Douglas L
|b 5
700 1 _ |a Jacobs, Andreas H
|b 6
700 1 _ |a Wyss-Coray, Tony
|b 7
700 1 _ |a Vitorica, Javier
|b 8
700 1 _ |a Ransohoff, Richard M
|b 9
700 1 _ |a Herrup, Karl
|b 10
700 1 _ |a Frautschy, Sally A
|b 11
700 1 _ |a Finsen, Bente
|b 12
700 1 _ |a Brown, Guy C
|b 13
700 1 _ |a Verkhratsky, Alexei
|b 14
700 1 _ |a Yamanaka, Koji
|b 15
700 1 _ |a Koistinaho, Jari
|b 16
700 1 _ |a Latz, Eicke
|0 P:(DE-2719)2000062
|b 17
700 1 _ |a Halle, Annett
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Petzold, Gabor C
|0 P:(DE-2719)2810273
|b 19
700 1 _ |a Town, Terrence
|b 20
700 1 _ |a Morgan, Dave
|b 21
700 1 _ |a Shinohara, Mari L
|b 22
700 1 _ |a Perry, V Hugh
|b 23
700 1 _ |a Holmes, Clive
|b 24
700 1 _ |a Bazan, Nicolas G
|b 25
700 1 _ |a Brooks, David J
|b 26
700 1 _ |a Hunot, Stéphane
|b 27
700 1 _ |a Joseph, Bertrand
|b 28
700 1 _ |a Deigendesch, Nikolaus
|b 29
700 1 _ |a Garaschuk, Olga
|b 30
700 1 _ |a Boddeke, Erik
|b 31
700 1 _ |a Dinarello, Charles A
|b 32
700 1 _ |a Breitner, John C
|b 33
700 1 _ |a Cole, Greg M
|b 34
700 1 _ |a Golenbock, Douglas T
|b 35
700 1 _ |a Kummer, Markus P
|0 P:(DE-HGF)0
|b 36
773 1 8 |a 10.1016/s1474-4422(15)70016-5
|b : Elsevier BV, 2015-04-01
|n 4
|p 388-405
|3 journal-article
|2 Crossref
|t The Lancet Neurology
|v 14
|y 2015
|x 1474-4422
773 _ _ |a 10.1016/S1474-4422(15)70016-5
|g Vol. 14, no. 4, p. 388 - 405
|0 PERI:(DE-600)2079704-7
|n 4
|q 14:4<388 - 405
|p 388-405
|t The lancet / Neurology
|v 14
|y 2015
|x 1474-4422
856 7 _ |2 Pubmed Central
|u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909703
856 4 _ |u https://pub.dzne.de/record/137851/files/DZNE-2020-04173_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/137851/files/DZNE-2020-04173_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:137851
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2000008
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2810593
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2000062
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2810273
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LANCET NEUROL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 25
|0 StatID:(DE-HGF)9925
|2 StatID
|b LANCET NEUROL : 2017
920 1 _ |0 I:(DE-2719)1011303
|k AG Heneka ; AG Heneka
|l Neuroinflammation, Biomarker
|x 0
920 1 _ |0 I:(DE-2719)1013024
|k AG Latz ; AG Latz
|l Innate Immunity in Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)1013020
|k AG Petzold ; AG Petzold
|l Vascular Neurology
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1011303
980 _ _ |a I:(DE-2719)1013024
980 _ _ |a I:(DE-2719)1013020
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21